
NANOBIOTIX EO-,03
Share · FR0011341205 · A1J7EB (XPAR)
4,11 EUR
09.06.2025 08:15
Current Prices from NANOBIOTIX EO-,03
Exchange | Ticker | Currency | Last Trade | Price | Daily Change |
---|---|---|---|---|---|
![]() London |
0QAV.L
|
EUR
|
09.06.2025 08:15
|
4,11 EUR
| 4,16 EUR
-1,20 %
|
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
-1,44 % | 10,34 % | 35,87 % | 30,48 % | 34,84 % | -23,46 % | -63,24 % |
Company Profile for NANOBIOTIX EO-,03 Share
Nanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.
Company Data
Name NANOBIOTIX EO-,03
Company Nanobiotix S.A.
Website
https://www.nanobiotix.com
Primary Exchange
Paris
WKN A1J7EB
ISIN FR0011341205
Asset Class Share
Sector Healthcare
Industry Medical - Pharmaceuticals
CEO Mr. Laurent Levy Ph.D.
Market Capitalization 141 Mio
Country France
Currency EUR
Employees 0,1 T
Address 60 rue de Wattignies, 75012 Paris
IPO Date 2014-02-13
Ticker Symbols
Name | Symbol |
---|---|
Frankfurt | 5NR.F |
London | 0QAV.L |
More Shares
Investors who NANOBIOTIX EO-,03 hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.